CASP3 and cervical carcinoma: Inhibition of caspase activity with a pan-caspase inhibitor, as confirmed by caspase-3 assay (Figure 6A), did not significantly alter SHetA2 cytotoxicity, suggesting that SHetA2 works independently of caspase activity in cervical cancer cell lines (Figure 6B).